Multicenter phase 2 study of axicabtagene ciloleucel for relapsed or refractory indolent non-Hodgkin lymphoma
Dr. Caron Jacobson
Most patients with advanced-stage indolent non-Hodgkin lymphoma have multiple relapses. The multicenter phase 2 ZUMA-5 trial evaluated axicabtagene ciloleucel autologous anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory indolent NHL (follicular lymphoma and marginal zone lymphoma). Axicabtagene ciloleucel showed high rates of durable responses and had a manageable safety profile.
